相关实验视频

Updated: May 23, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

TP53 - 突变骨髓瘤:2024年关于诊断,风险分层和管理的更新

Mithun Vinod Shah¹, Daniel A Arber², Devendra K Hiwase^3,4,5

¹Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

American journal of hematology

|March 11, 2025

概括

骨髓瘤 (MN) 中的TP53突变会导致侵袭性疾病和不良结果. 目前的治疗方法提供了有限的生存益处,需要对TP53-突变MN的诊断和治疗进行审查.

科学领域:

血液学血液学血液学
在瘤学瘤学.
癌症遗传学癌症遗传学

背景情况:

TP53基因突变在侵袭性癌症中普遍存在,特别是在8%-12%的骨髓质疏松症候群 (MDS) 和急性骨髓性白血病 (AML) 中.
TP53-突变骨髓瘤 (MN) 与化学抵抗,预后不佳有关,在老年人群和先前癌症治疗的幸存者中越来越常见.
抗BCL-2抑制剂venetoclax和其他强化治疗方法在改善TP53突变MN患者的存活率方面表现出有限的有效性.

研究的目的:

审查TP53-突变骨髓瘤瘤 (MN) 的生物学,诊断和治疗方面的最新进展.
分析世界卫生组织和国际共识分类对TP53突变的MN之间的差异及其对风险评估的影响.
讨论当前的治疗场景和管理TP53突变的MN的局限性.

主要方法:

关于TP53突变的MN最近进展的文献综述.
对TP53突变的MN的分类系统 (世卫组织和国际共识) 的分析.
对TP53突变的MN的当前和新兴治疗策略的审查.

主要成果:

TP53突变的MN被认为是一个独立的实体,但存在分类差异,可能会影响预后风险评估.
前体TP53突变的克隆可以在白血病转化前几年被检测出来,这表明早期干预的潜力.
目前的治疗方法,包括密集化疗和venetoclax,在显著改善TP53突变的MN的生存率方面表现出有限的有效性.

结论:

由于固有的化学抵抗和糟糕的结果,TP53突变的MN存在重大治疗挑战.
分类系统中的差异需要仔细考虑,以准确地分层和管理风险.
进一步的研究和新的治疗策略至关重要,以改善TP53突变的MN患者的治疗结果.

关键词:

AML分子诊断和治疗方法骨髓分裂性综合征是什么?骨髓性白血病和骨质疏松症的新生病.在p53中,p53是什么?

更多相关视频

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...